UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

 

Filed by the Registrant x

 

Filed by a Party other than the Registrant o

 

Check the appropriate box:

 

¨Preliminary Proxy Statement

 

oConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

oDefinitive Proxy Statement

 

xDefinitive Additional Materials

 

oSoliciting Material Pursuant to §240.14a-12

 

Alliqua BioMedical, Inc.

 

(Name of Registrant as Specified In Its Charter)

 

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

xNo fee required.

 

oFee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

(1)Title of each class of securities to which transaction applies:

 

 
(2)Aggregate number of securities to which transaction applies:

 

 
(3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

 
(4)Proposed maximum aggregate value of transaction:

 

 
(5)Total fee paid:

 

 

 

oFee paid previously with preliminary materials.

 

oCheck box if any part of the fee is offset as provided by Exchange Act Rule 0-11 and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

(1)Amount Previously Paid:

 

 
(2)Form, Schedule or Registration Statement No.:

 

 
(3)Filing Party:

 

 
(4)Date Filed:

 

 

 

 

 

 

Alliqua BioMedical, Inc.
1010 Stony Hill Road, Suite 200
Yardley, PA 19067
Telephone: (215) 702-8550

 

SUPPLEMENT TO PROXY STATEMENT

FOR THE ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON JUNE 23, 2017

 

This supplement updates the Definitive Proxy Statement, dated May 9, 2017, previously furnished to stockholders of Alliqua BioMedical, Inc. in connection with the Annual Meeting of Stockholders of Alliqua BioMedical, Inc. to be held on June 23, 2017 (the “Annual Meeting”). Unless the context otherwise requires, references herein to “we”, “us”, “our” or the “Company” refer to Alliqua BioMedical, Inc., a Delaware corporation.

 

Broker Non-Vote

 

A broker non-vote occurs when a broker holding shares for a beneficial owner does not vote on a particular proposal because the broker does not have discretionary voting power with respect to that item and has not received voting instructions from the beneficial owner. Notwithstanding the information contained in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on May 9, 2017 (the “Proxy Statement”), we expect that banks, brokers, and other nominees will have discretionary authority to vote your shares on two proposals: the Reverse Stock Split Proposal (Proposal 2) and the proposal to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017 (Proposal 7). If you do not provide voting instructions, we expect that your bank, broker or other nominee will be permitted to vote your shares on each of these proposals.

 

We do not expect that that banks, brokers and other nominees will be allowed to vote on all other proposals included in the Proxy Statement unless they have received voting instructions from the beneficial owner of the shares.

 

Important Information

 

This supplement should be read in conjunction with the Proxy Statement. To the extent that information in this supplement differs from or updates information contained in the Proxy Statement, the information in this supplement controls. The Proxy Statement is available to stockholders at www.proxyvote.com.

 

The date of this supplement to the Proxy Statement is June 16, 2017.